DOYLESTOWN, Pa., March 24 /PRNewswire/ -- Avidas(TM) Pharmaceuticals, a privately held, specialty pharmaceutical company which focuses on dermatology and women's health, today announced the launch of Scalacort(TM) DK (defence kit), that offers three scalp solutions in one patient convenience kit.
Scalacort DK includes Scalacort (hydrocortisone lotion USP) 2%, a fast-drying, non-greasy, corticosteroid in a clear fragrance-free base. Scalacort relieves itching and inflammation of the scalp in areas where greasy ointments and creams may not be cosmetically appealing. For added patient convenience Scalacort DK also includes the following complimentary products: defence(TM) medicated shampoo, a professional-strength medicated shampoo formulated with 2% salicylic acid and 2% micronized colloidal sulfur to control the flaking and scaling of seborrheic dermatitis and scalp psoriasis; and defence(TM) gentle cleansing shampoo, a color- and fragrance-free, non-irritating shampoo designed to be used daily on all hair types. Scalacort DK is available by prescription only.
Seborrheic dermatitis (also known as seborrheic eczema) is one of the most common cutaneous disorders affecting approximately eight million Americans. According to the American Academy of Dermatology (AAD), seborrheic dermatitis cannot be cured but in most cases will respond quickly to proper treatment. The goals of treatment are to loosen and remove scales and crusts, prevent skin infections, as well as reduce the inflammation and itch. Scalp psoriasis, another common skin disorder affecting approximately four million Americans, shares the same treatment goals of removing scales and crusts along with reducing inflammation and itch.
"Patient convenience is important to treatment outcomes," said Millburn, New Jersey dermatologist Dr. Gail H. Mautner. "With Scalacort DK physicians can, with one prescription, provide their patients with three scalp products in a single convenience kit."
A valuable patient prescription co-pay coupon is available at http://www.ScalacortDK.com
Scalacort is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Important Safety Information:
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.
Please see Scalacort full prescribing information at http://www.ScalacortDK.com
About Seborrheic Dermatitis:
Seborrheic dermatitis is a chronic inflammatory disorder affecting areas of the head and trunk where sebaceous glands are most prominent. Lipophilic yeasts of the Malassezia genus, as well as genetic, environmental and general health factors, contribute to this disorder. Scalp seborrhea varies from mild dandruff to dense, diffuse, adherent scale.
Facial and trunk seborrhea is characterized by powdery or greasy scale in skin folds and along hair margins.
About Scalp Psoriasis:
Psoriasis is a chronic, non-contagious autoimmune disease which affects the skin and joints. It commonly causes red scaly patches to appear on the skin. The scaly patches caused by psoriasis, called psoriatic plaques, are areas of inflammation and excessive skin production. Skin rapidly accumulates at these sites and takes on a silvery-white appearance. Approximately half of the people who have psoriasis have scalp psoriasis.
Avidas Pharmaceuticals is a privately held company focused on the therapeutic areas of dermatology and women's health. The company acquires, develops, and maximizes the potential of acquired products through focused selling and precision marketing. The Company is headquartered in Doylestown, PA. http://www.avidaspharma.com
Contact: Avidas Pharmaceuticals, LLC, Greg Gironda, 267-895-1755, email@example.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE Avidas Pharmaceuticals, LLC|
Copyright©2009 PR Newswire.
All rights reserved